RWML
URGN icon

RAFFA WEALTH MANAGEMENT, LLC’s UroGen Pharma URGN Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42
Closed -$366 – 1171
2022
Q1 		$366 Hold
42
– – ﹤0.01% 1084
2021
Q4 		$399 Hold
42
– – ﹤0.01% 1085
2021
Q3 		$706 Buy
+42
New +$666 ﹤0.01% 966

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's URGN Position: Q2 2022 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 42 shares — an estimated $366 sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in URGN in Q3 2021 and held it in 3 quarters. The position peaked at $706 in Q3 2021. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

  • RAFFA WEALTH MANAGEMENT, LLC reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
  • RAFFA WEALTH MANAGEMENT, LLC sold 42 UroGen Pharma shares in Q2 2022, an estimated $366.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in UroGen Pharma in Q3 2021 and held it in 3 quarters.
  • RAFFA WEALTH MANAGEMENT, LLC's UroGen Pharma position peaked at $706 in Q3 2021.
  • 65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2022, filed 27 Jul 2026.